CA3099450A1 - Bispecific antibodies with cleavable c-terminal charge-paired tags - Google Patents

Bispecific antibodies with cleavable c-terminal charge-paired tags Download PDF

Info

Publication number
CA3099450A1
CA3099450A1 CA3099450A CA3099450A CA3099450A1 CA 3099450 A1 CA3099450 A1 CA 3099450A1 CA 3099450 A CA3099450 A CA 3099450A CA 3099450 A CA3099450 A CA 3099450A CA 3099450 A1 CA3099450 A1 CA 3099450A1
Authority
CA
Canada
Prior art keywords
amino acid
domain
polypeptide
acid residues
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099450A
Other languages
English (en)
French (fr)
Inventor
John K KAWOOYA
Alex W JACOBITZ
Christopher MOHR
Stephen Smith
Kevin Graham
Ray Lieh Yoon LOW
Oliver Thiel
Dante ROMANINI
Victoria WAGNER
Neeraj J AGRAWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3099450A1 publication Critical patent/CA3099450A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3099450A 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags Pending CA3099450A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668626P 2018-05-08 2018-05-08
US62/668,626 2018-05-08
PCT/US2019/031379 WO2019217587A1 (en) 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags

Publications (1)

Publication Number Publication Date
CA3099450A1 true CA3099450A1 (en) 2019-11-14

Family

ID=66676901

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099450A Pending CA3099450A1 (en) 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags

Country Status (8)

Country Link
US (2) US12384849B2 (https=)
EP (1) EP3790904A1 (https=)
JP (3) JP2021523101A (https=)
AU (2) AU2019265699B2 (https=)
CA (1) CA3099450A1 (https=)
MA (1) MA52571A (https=)
MX (2) MX2020011844A (https=)
WO (1) WO2019217587A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220363770A1 (en) * 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
US20250388669A1 (en) * 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
CA2377513A1 (en) 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2004047762A2 (en) * 2002-11-25 2004-06-10 Chiron Corporation Methods for treating cancer using porimin as a target
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
MX340696B (es) * 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10077299B2 (en) * 2013-04-25 2018-09-18 Abtlas Co., Ltd. Method for refining protein including self-cutting cassette and use thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
EP3307321A4 (en) 2015-08-26 2019-04-17 Bison Therapeutics Inc. MULTISPECIFIC ANTIBODY PLATFORM AND ASSOCIATED METHODS

Also Published As

Publication number Publication date
WO2019217587A1 (en) 2019-11-14
JP2021523101A (ja) 2021-09-02
AU2019265699A1 (en) 2021-01-07
AU2019265699B2 (en) 2026-03-12
JP2026035775A (ja) 2026-03-04
MX2025001939A (es) 2025-04-02
MA52571A (fr) 2021-03-17
EP3790904A1 (en) 2021-03-17
US12384849B2 (en) 2025-08-12
JP2024023264A (ja) 2024-02-21
US20220089756A1 (en) 2022-03-24
JP7785734B2 (ja) 2025-12-15
AU2026201242A1 (en) 2026-04-23
US20250197518A1 (en) 2025-06-19
MX2020011844A (es) 2021-04-13

Similar Documents

Publication Publication Date Title
JP7250863B2 (ja) カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用
KR101586128B1 (ko) 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
TWI359027B (en) Bivalent, bispecific antibodies
US20250197518A1 (en) Bispecific antibodies with cleavable c-terminal charge-paired tags
TW201100543A (en) Tri-or tetraspecific antibodies
KR20160029128A (ko) 이중특이적 cd3 및 cd19 항원 결합 구조체
TW200932271A (en) Bivalent, bispecific antibodies
TW202400642A (zh) 抗ＣＤ２８ｘ抗ＰＳＭＡ抗體
JP2025542327A (ja) 新規抗ｇｐｒｃ５ｄ抗体
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20220144956A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
US20240034815A1 (en) Heterodimeric antibodies that bind cd3 and gpc3
CN121487967A (zh) 抗cd28 x抗enpp3抗体
ES3040852T3 (en) Engineering charge pair mutations for pairing of hetero-igg molecules
AU2018292438B2 (en) Stabilized chimeric fabs
US20210284717A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
CA3064966C (en) Stabilized chimeric fabs
WO2025237931A1 (en) Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
WO2026056998A1 (zh) Gipr结合分子及医药用途
WO2025041077A1 (en) Ctla-4-based lysosomal degraders and uses thereof
CN117377689A (zh) 结合cd3和gpc3的异二聚抗体
RU2826203C1 (ru) Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение
HK40099262A (zh) 稳定化的tcr构建体及使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251009

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421